ContraFect Corporation announced that on April 1, 2019, Steven C. Gilman notified the company of his resignation as President and Chief Executive Officer and Chairman of the Board, effective on April 2, 2019. Dr. Gilman will remain a director of the company, and was appointed to serve as Vice Chairman of the Board and as Chairman of the Company's Science and Technology Committee, effective on April 2, 2019. As a result of Dr. Gilman's resignation, the Board appointed Roger J. Pomerantz, M.D., F.A.C.P. as President and Chief Executive Officer and Chairman of the Board, effective on April 2, 2019.

As a result of his appointment, the Board determined that Dr. Pomerantz no longer qualifies as independent under the rules of The Nasdaq Stock Market, LLC and Rule 10A-3 under the Securities and Exchange Act of 1934, as amended. The Board therefore removed Dr. Pomerantz as a member of the Audit Committee and appointed Isaac Blech as a member of the Audit Committee, effective on April 2, 2019. The Board determined that Mr. Blech is independent under the Nasdaq Rules and Rule 10A-3 for service as a member of the Audit Committee.

Dr. Pomerantz was most recently Chairman and CEO of Seres Therapeutics, where he now continues as the company's Chairman of the Board of Directors.